JCB, Volume 16, Number 3, 2010 Editorial Vol.16 No. 3 (2010) Increasing clarity Yali Friedman The fates of biotechnology companies, like those in many other dynamic industries, depend on the outcome of future events, which can be difficult to predict. Seemingly late Commentary Vol.16 No. 3 (2010) Personalized medicine and oncology: A commentary and key questions Robert Freeman   Article Vol.16 No. 3 (2010) Market access – An essential investment before drug launch Sean McGrath Before introducing a new pharmaceutical/biopharmaceutical agent into clinical practice, local decision makers need to consider not only the cost Article Vol.16 No. 3 (2010) Rethinking commercial strategy – A patient-centered commercial model Sanjay K Rao That the bio/pharmaceutical industry faces daunting challenges is common knowledge and the subject of debate for some time now. In reaction, lea Article Vol.16 No. 3 (2010) Pathways to biomedical tipping points: Vertical, horizontal or other? Mark J Ahn Breakthrough innovations in biomedical technologies such as treatments, devices and diagnostics are increasingly addressing complex medical needs and yielding significa Article Vol.16 No. 3 (2010) Key drivers influencing the commercialization of ethanol-based biorefineries Anuj K Chandel The imposition of ethanol derived from biomass for blending in gasoline would make countries less dependent on current petroleum sources, which would save foreign excha Article Vol.16 No. 3 (2010) Made in India: Are you ready for outsourced contract manufacturing? Andrew Lees Within the biotechnology industry, the number of US–India collaborations is on the rise. However, there are several reoccurring problems many US firms identify i Intellectual Property Management Vol.16 No. 3 (2010) Controlling costs in patent litigation Catherine Rajwani This article provides the top 10 ways that clients can reduce their litigation costs. The article explains the types of costs that are incurred in patent litigation and Legal and Regulatory Updates Vol.16 No. 3 (2010) Gene patent considered by English Court of Appeal Philip Webber   Legal and Regulatory Updates Vol.16 No. 3 (2010) Commentary regarding decision in Myriad Genetics on ‘isolated’ DNA claims Thomas J Kowalski   Book Review Vol.16 No. 3 (2010) Book Review: Biotechnology: A Comprehensive Training Guide for the Biotechnology Industry James Harber Biotechnology: A Comprehensive Training Guide for the Biotechnology IndustrySyed Imtiaz Haider and Anika AshtokCRC Press, 2009, paperback, 868pp.,ISBN: 978-1420084481